Marcos L. Sznaidman

Array ( [id] => 18656070 [patent_doc_number] => 20230301938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => TREATMENT OF COVID-19 ASSOCIATED COGNITIVE DYSFUNCTION BY NUTRACEUTICAL PREPARATIONS [patent_app_type] => utility [patent_app_number] => 18/106925 [patent_app_country] => US [patent_app_date] => 2023-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18106925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434254 [patent_doc_number] => 20230181548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE [patent_app_type] => utility [patent_app_number] => 18/164587 [patent_app_country] => US [patent_app_date] => 2023-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418383 [patent_doc_number] => 20230172841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/103404 [patent_app_country] => US [patent_app_date] => 2023-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18103404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522934 [patent_doc_number] => 20230233584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => EXTENDED RELEASE 5-HT RECEPTOR AGONISTS FOR NEUROLOGICAL CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/102268 [patent_app_country] => US [patent_app_date] => 2023-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18102268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389773 [patent_doc_number] => 20230157991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE AND CHRONIC PAIN, CONTAINING POLMACOXIB AND TRAMADOL [patent_app_type] => utility [patent_app_number] => 18/158284 [patent_app_country] => US [patent_app_date] => 2023-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877396 [patent_doc_number] => 20240000765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => COMBINATION TREATMENT OF LIVER DISORDERS [patent_app_type] => utility [patent_app_number] => 18/157216 [patent_app_country] => US [patent_app_date] => 2023-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18157216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19410533 [patent_doc_number] => 12076325 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent [patent_app_type] => utility [patent_app_number] => 18/099200 [patent_app_country] => US [patent_app_date] => 2023-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 30 [patent_no_of_words] => 13673 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18099200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738290 [patent_doc_number] => 12215108 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Development of potential antidotes for arsenicals [patent_app_type] => utility [patent_app_number] => 18/095429 [patent_app_country] => US [patent_app_date] => 2023-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 43681 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 539 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18095429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483528 [patent_doc_number] => 20230210826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => DRUG COMBINATION FOR TREATING OBESITY [patent_app_type] => utility [patent_app_number] => 18/151232 [patent_app_country] => US [patent_app_date] => 2023-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3713 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752377 [patent_doc_number] => 20230355609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => Spirolactone Compounds [patent_app_type] => utility [patent_app_number] => 18/092723 [patent_app_country] => US [patent_app_date] => 2023-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18092723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18707488 [patent_doc_number] => 20230330062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS [patent_app_type] => utility [patent_app_number] => 18/068682 [patent_app_country] => US [patent_app_date] => 2022-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170781 [patent_doc_number] => 20240156755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => USE OF RIP1 INHIBITOR OR MLKL INHIBITOR FOR TREATING OR PREVENTING HEREDITARY RETINAL DYSTROPHY [patent_app_type] => utility [patent_app_number] => 18/085119 [patent_app_country] => US [patent_app_date] => 2022-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18085119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484847 [patent_doc_number] => 20230212155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => PD-1/PD-L1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/060934 [patent_app_country] => US [patent_app_date] => 2022-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 1236 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18374300 [patent_doc_number] => 20230149378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/993003 [patent_app_country] => US [patent_app_date] => 2022-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17993003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18915729 [patent_doc_number] => 11877995 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases [patent_app_type] => utility [patent_app_number] => 17/992162 [patent_app_country] => US [patent_app_date] => 2022-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 5604 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17992162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18310727 [patent_doc_number] => 20230114627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => COMPOSITION COMPRISING A METAL ASCORBO-CAMPHORATE COMPOUND AND METHOD FOR PREVENTION AND/OR TREATMENT OF PAPILLOMAVIRUS INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/991581 [patent_app_country] => US [patent_app_date] => 2022-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17991581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18257228 [patent_doc_number] => 20230084268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => ANTIBACTERIAL AND BIOFILM FORMATION-INHIBITING COMPOSITION CONTAINING MYRISTOLEIC ACID AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/989705 [patent_app_country] => US [patent_app_date] => 2022-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17989705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18257228 [patent_doc_number] => 20230084268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => ANTIBACTERIAL AND BIOFILM FORMATION-INHIBITING COMPOSITION CONTAINING MYRISTOLEIC ACID AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/989705 [patent_app_country] => US [patent_app_date] => 2022-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17989705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19975861 [patent_doc_number] => 12343317 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Compositions and methods for treating bleeding and bleeding disorders [patent_app_type] => utility [patent_app_number] => 17/983844 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 51 [patent_no_of_words] => 22552 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17983844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449467 [patent_doc_number] => 20230190743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS) [patent_app_type] => utility [patent_app_number] => 17/981033 [patent_app_country] => US [patent_app_date] => 2022-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17981033 [rel_patent_id] =>[rel_patent_doc_number] =>)